Last 12 months
Inside the activity.
2 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 2 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2016 Filed Nov 2, 2016 00:45 UTC |
Hertzberg Richardsignificant owner
|
SaleCellectar Biosciences, Inc. common stock (CLRB) | 21,000 | $2.03 | $42,609.00 |
DisclosureSEC source: 0001676051-16-000006 · primary_doc.xml · nonDerivative · entry 1 Hertzberg Richard · CIK 0001676051 · significant owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 F1 · security: CLRB stock sales during period October 13 through October 31, 2016 Read SEC document |
| August 09, 2016 Filed Nov 2, 2016 00:45 UTC |
Hertzberg Richardsignificant owner
|
SaleCellectar Biosciences Inc. Warrant (CLRBW) · Derivative | 40,916 | $1.75 Strike: $46.80 | $71,603.00 |
DisclosureSEC source: 0001676051-16-000006 · primary_doc.xml · derivative · entry 2 Hertzberg Richard · CIK 0001676051 · significant owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Cellectar Biosciences, Inc. common stock (CLRB) · 40,916 shares Expires 2019-08-20 F2 · security: Price of CLRB at close of market 11/1/2016 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.